1. Scrip
  2. >>R&D

BIO-Europe Spring 2019: Themis Bioscience Harnesses Measles Vector For Immune Modulation

 
• By Mike Ward

Themis Bioscience CEO Erich Tauber outlined the company’s work in immune modulation in an interview at BIO-Europe Spring 2019.

Video interview
Themis Bioscience CEO Erich Tauber speaks to Scrip

Themis Bioscience has developed a viral vector platform based on the measles vaccine to deliver transgenes that reprogram the immune system’s response to infectious diseases and cancer. The Vienna, Austria-based firm’s most advanced program is a vaccine in Phase III studies for chikungunya. CEO Erich Tauber explained the company’s approach to Mike Ward.

Open Media

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.